- Lobbying
- Lobbying by RX Bio, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
John Donnelly | Rep. Tom Graves: CoS (2015-21), Dpty CoS/Comm Dir. (2014-15), Comm Dir. (2012-14 and 2010-11). Sen. Scott Brown: Press Secy (2011-12). Rep. Dan Burton: Press Secy (2008-10); Special Asst. (2007-08) |
Colby Miller | Defense & Foreign Policy Advisor, Sen Hutchinson (07-09); Military LA, Rep. Roscoe Bartlett (05-07); Navy Congressional Liaison (03-05). |
Joe Kasper | US Dept. Homeland Security: Depty. Asst. Secy (2020), Office of the Secy of Defense: Special Asst (2017-2020); Rep. Duncan Hunter: Chief of Staff (2014-2017); LD/Communications Dir (2008-9); Communications Dir. (2004-2008); LA (2003-2004) |
Allison Feikes | Sen. Mike Braun, Senior Policy Advisor 2021, LA 2019-2021; Rep. Barbara Comstock, LA November 2017 - January 2019; Sen. Mitch McConnell -District and Community Outreach Intern, 2012. |
Jim Ervin | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Q3 Report
Amendment
Q2 Report
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Promote RxBio's biomedical research and advancements among Congressional, Department of Defense and other federal stakeholders, with primary focus on the FY22 budget cycle and securing federal support in alignment with RxBio's enduring partnership with the University of Tennessee..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate